LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
De Luca, Maria Teresa; Meringolo, Maria; Spagnolo, Primavera Alessandra; Badiani, Aldo (2012)
Publisher: De Gruyter
Languages: English
Types: Article
Subjects: B
Drug abuse is often seen as a unitary phenomenon, partly as a result of the discovery over the past three decades of shared mechanisms of action for addictive substances. Yet the pattern of drug taking is often very different from drug to drug. This is particularly evident in the case of 'club drugs', such as ketamine. Although the number of ketamine abusers is relatively small in the general population, it is quite substantial in some settings. In particular, ketamine abuse is almost exclusively limited to clubs and large music parties, which suggests a major role of context in modulating the reward effects of this drug. This review focuses on recent preclinical and clinical findings, including previously unpublished data, that provide evidence that, even under controlled conditions, ketamine reward is a function of the setting of drug taking.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Adler, C.M., Malhotra, A.K., Elman, I., Goldberg, T., Egan, M., Pickar, D., and Breier, A. (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 156, 1646-1649.
    • Anis, N.A., Berry, S.C., Burton, N.R., and Lodge, D. (1983). The dissociative anesthetics ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br. J. Pharmacol. 79, 565-575.
    • Aro, S. (1981). Stress, morbidity, and health-related behaviour. A five-year follow-up study among metal industry employees. Scand. J. Soc. Med. Suppl. 25, 1-130.
    • Aroni, F., Iacovidou, N., Dontas, I., Pourzitaki, C., and Xanthos, T. (2009). Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J. Clin. Pharmacol. 49, 957-964.
    • Badiani, A., Belin, D., Epstein, D., Calu, D., and Shaham, Y. (2011). Opiate versus psychostimulant addiction: the differences do matter. Nature Rev. Neurosci. 12, 685-700.
    • Baumgartner, E. (2007). Ketamin als Partydroge. Zum Risiko konsum bedingter sozial pathologischer Veranderungen und spezifischer Konfliktmuster sowie deren Relevanz fur sekundar praventive Einrichtungen (Verein: Wiener).
    • Bergman, S.A. (1999). Ketamine: Review of its pharmacology and its use in pediatric anesthesia. Anesth. Prog. 46, 10-20.
    • Bevan, R.K., Rose, M.A., and Duggan, K.A. (1997). Evidence for direct interaction of ketamine with alpha 1- and beta 2-adrenoceptors. Clin. Exp. Pharmacol. Physiol. 24, 923-926.
    • Bowdle, T.A., Radant, A.D., Cowley, D.S., Kharasch, E.D., Strassman, R.J., and Roy-Byrne, P.P. (1998). Psychedelic effects of ketamine in healthy volunteers. Anesthesiology 88, 82-88.
    • Brady, K.T., Dansky, B.S., Back, S.E., Foa, E.B., and Carroll, K.M. (2001). Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: Preliminary findings. J. Subst. Abuse Treat. 21, 47-54.
    • Brown, J.T., Davis, M.I., Jason, L.A., and Ferrari, J.R. (2006). Stress and coping: The roles of ethnicity and gender in substance abuse recovery. J. Prev. Interv. Community 31, 75-84.
    • Caprioli, D., Celentano, M., Paolone, G., and Badiani, A. (2007a). Modeling the role of environment in addiction. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 1639-1653.
    • Caprioli, D., Paolone, G., Celentano, M., Testa, A., Nencini, P., and Badiani, A. (2007b). Environmental modulation of cocaine self-administration in the rat. Psychopharmacol. (Berl) 192, 397-406.
    • Caprioli, D., Celentano, M., Paolone, G., Lucantonio, F., Bari, A., Nencini, P., and Badiani, A. (2008). Opposite environmental regulation of heroin and amphetamine self-administration in the rat. Psychopharmacol. (Berl) 198, 395-404.
    • Caprioli, D., Celentano, M., Dubla, A., Lucantonio, F., Nencini, P., and Badiani, A. (2009). Ambience and drug choice: Cocaine and heroin-taking as a function of environmental context in humans and rats. Biol. Psychiatry 65, 893-899.
    • Carpenter, W.T. Jr. (1999). The schizophrenia ketamine challenge study debate. Biol. Psychatry 46, 1081-1091.
    • Celentano, M., Caprioli, D., Dipasquale, P., Cardillo, V., Nencini, P., Gaetani, S., and Badiani, A. (2009). Drug context differently regulates cocaine versus heroin self-administration and cocaine- versus heroin-induced Fos mRNA expression in the rat. Psychopharmacol. (Berl) 204, 349-360.
    • Chakraborty, K., Neogi, R., and Basu, D. (2010). Clubs drugs: review of the 'rave' with a note of concern for the Indian scenario. Indian J. Med. 133, 594-604.
    • Childress, A.R., McLellan, A.T., and O'Brien, C.P. (1984). Assessment and extinction of conditioned withdrawal-like responses in an integrated treatment for opiate dependence. NIDA Res. Monogr. 55, 202-210.
    • Childress, A.R., McLellan, A.T., and O'Brien, C.P. (1986). Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. Br. J. Addict. 81, 655-660.
    • Clark, H.W., Masson, C.L., Delucchi, K.L., Hall, S.M., and Sees, K.L. (2001). Violent traumatic events and drug abuse severity. J. Subst. Abuse Treat. 20, 121-127.
    • Collins, R.J., Weeks, J.R., Cooper, M.M., Good, P.I., and Russel, R.R. (1984). Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacol. (Berl) 82, 6-13.
    • Copeland, J. and Dillon, P. (2005). The health and psycho-social consequences of ketamine use. Int. J. Drug Policy 16, 122-131.
    • Cornish, J.L., Shahnawaz, Z., Thompson, M.R.,Wong, S,. Morley, K.C., Hunt, G.E., and McGregor, I.S. (2003). Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur. J. Pharmacol. 482, 339-41.
    • Correll, G.E., Maleki, J., Gracely, E.J., Muir, J.J., and Harbut, R.E. (2004). Subanesthetic ketamine infusion therapy: A retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 5, 263-75.
    • Crisp, T., Perrotti, J.M., Smith, D.L., Stafinsky, J.L., and Smith, D.J. (1991). The local monoaminergic dependency of spinal ketamine. Eur. J. Pharmacol. 194, 167-72.
    • Curran, H.V. and Morgan, C. (2000). Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 95, 575-590.
    • Dalgarno, P.J. and Shewan, D. (1996). Illicit use of ketamine in Scotland. J. Psychoact. Drugs 28, 191-199.
    • De Luca, M.T. and Badiani, A. (2011). Ketamine self-administration in the rat: Evidence for a critical role of setting. Psychopharmacol. (Berl) 214, 549-556.
    • Degenhardt, L. and Dunn, M. (2008). The epidemiology of GHB and ketamine use in an Australian household survey. Int. J. Drug Policy 19, 311-316.
    • Dillon, P., Copeland, J., and Jansen, K. (2001). Patterns of use and harms associated with non-medical ketamine use. NDARC Technical Report No. 111 (Sydney, NSW, Australia: University of New South Wales). Available at http://ndarc.med.unsw. edu.au/resource/patterns-use-and-harms-associated-nonmedical-ketamine-use.
    • Dillon, P., Copeland, J., and Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 69, 23-28.
    • Domino, E.F., Chodoff, P., Corssen, G. (1965). Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. 6, 279-291.
    • EMCDDA (2007). National Report 2007: Austria (Lisbon: European Monitoring Centre for Drugs and Drug Addiction). Available at http://www.emcdda.europa.eu/publications/searchresults? action=list&type=PUBLICATIONS&SERIES_PUB=w203.
    • EMCDDA (2010a). National Report 2010: Austria. (Lisbon: European Monitoring Centre for Drugs and Drug Addiction). Available at http://www.emcdda.europa.eu/publications/searchresults? action=list&type=PUBLICATIONS&SERIES_PUB=w203.
    • EMCDDA (2010b). National Report 2010: Czech Republic. (Lisbon: European Monitoring Centre for Drugs and Drug Addiction). Available at http://www.emcdda.europa.eu/publications/ searchresults?action=list&type=PUBLICATIONS&SERIES_ PUB=w203.
    • EMCDDA (2010c). National Report 2010: France. (Lisbon: European Monitoring Centre for Drugs and Drug Addiction). Available at http://www.emcdda.europa.eu/publications/searchresults? action=list&type=PUBLICATIONS&SERIES_PUB=w203.
    • EMCDDA (2010d). National Report 2010: The Netherlands. (Lisbon: European Monitoring Centre for Drugs and Drug Addiction). Available at http://www.emcdda.europa.eu/publications/ searchresults?action=list&type=PUBLICATIONS&SERIES_ PUB=w203.
    • EMCDDA (2011). Annual Report on the State of the Drugs Problem in Europe. (Lisbon: European Monitoring Centre for Drugs and Drug Addiction). Available at http://www.emcdda.europa.eu/ publications/annual-report/2011.
    • Engelhardt, W. (1997). Recovery and psychomimetic reactions following S-(+)-ketamine. Anaesthesist 46(Suppl 1), S38-42.
    • Fink, A.D. and Ngai, S.H. (1982). Opiate receptor mediation of ketamine analgesia. Anesthesiology 56, 291-297.
    • Fujikawa, D.G. (1995). Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 36, 186-95.
    • Gill, P.A. (1993). Non-medical use of ketamine. Br. Med. J. 306, 601-602.
    • Gonzalez, P., Cabello, P., Germany, A., Norris, B., and Contreras, E. (1997). Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur. J. Pharmacol. 332, 257-262.
    • Green, S.M. and Johnson, N.E. (1990). Ketamine sedation for pediatric procedures: Part 2, review and implications. Ann. Emerg. Med. 19, 1033-1046.
    • Gupta, A., Devi, L.A., and Gomes, I. (2011). Potentiation of -μopioid receptor mediated signaling by ketamine. Neurochem. 119, 294-302.
    • Hancock, P.J. and Stamford, J.A. (1999). Stereospecific effects of ketamine on dopamine efflux and uptake in the rat nucleus accumbens. Br. J. Anaesth. 82, 603-608.
    • Hartvig, P., Valtysson, J., Lindner, K.J., Kristensen, J., Karlsten, R., Gustafsson, L.L., Persson, J., Svensson, J.O., Oye, I., Antoni, G., et al. (1995). Central nervous system effects of sub dissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin. Pharmacol. Ther. 58, 165-173.
    • Hoare, J. (2009). Drug Misuse Declared: Findings from the 2008/09 British Crime Survey England and Wales. (London: Home Office Statistical Board).
    • Izquierdo, I. and Medina, J.H. (1995). Correlation between the pharmacology of long-term potentiation and the pharmacology of memory. Neurobiol. Learn. Mem. 63, 19-32.
    • Jansen, K. (2004). Ketamine: Dreams and Realities (Sarasota, FL: M.A.P.S.).
    • Ji, D., Sui, Z.Y., Ma, Y.Y., Luo, F., Cui, C.L., and Han, J.S. (2004). NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem. Res. 29, 2113-2120.
    • Joe Laidler, K.A. (2005). The rise of club drugs in a heroin society: The case of Hong Kong. Subst. Use Misuse 40, 1257-1278.
    • Johnston, L.D., O'Malley, P.M., Bachman, J.G., and Schulenberg, J.E. (2009). Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings (Bethesda, MD: National Institute on Drug Abuse).
    • Kapur, S. and Seeman, P. (2002). NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5- HT(2)receptors-implications for models of schizophrenia. Mol. Psychiatry 7, 837-844.
    • Klebaur, J.E., Phillips, S.B., Kelly, T.H., and Bardo, M.T. (2001). Exposure to novel environmental stimuli decreases amphetamine self-administration in rats. Exp. Clin. Psychopharmacol. 9, 372-379.
    • Krupitsky, E.M. and Grinenko, A.Y. (1997). Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J. Psychoact. Drugs 29, 165-183.
    • Krystal, J.H. (2007). Ketamine and the potential role for rapid acting antidepressant medications. Swiss Med. Wkly. 137, 215-216.
    • LeDoux, J.E. (1996). The Emotional Brain (New York: Simon and Schuster).
    • LeDoux, J. (2012). Rethinking the emotional brain. Neuron 73, 653-676.
    • Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., and Duman, R.S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
    • Lindefors, N., Barati, S., and O'Conor, W.T. (1997). Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in the rat medial prefrontal cortex. Brain Res. 759, 205-212.
    • Lynch, M.E., Clark, A.J., Sawynok, J., and Sullivan, M.J. (2005). Topical amitriptyline and ketamine in neuropathic pain syndromes: An open-label study. J. Pain. 6, 644-649.
    • Measham, F., Aldridge, J., and Parker, H. (2001). Dancing on Drugs: Risk, Health and Hedonism (London: Free Association Books).
    • Moore, K. (2004). A commitment to clubbing. Peace review. J. Social Justice 16, 459-456.
    • Moore, K. and Measham, F. (2008). “It's the most fun you can have for twenty quid”: motivations, consequences and meanings of british ketamine use. Addiction Res. Theory 16, 231-244.
    • Morgan, C. and Curran, H.V. (2011). Ketamine use: a review. Addiction. 107, 27-38.
    • Newcombe, R. (2008). Ketamine case study: the phenomenology of a ketamine experience. Addict. Res. Theory 16, 209-215.
    • Ompad, D.C., Ikeda, R.M., Shah, N., Fuller, C.M., Bailey, S., Morse, E., Kerndt, P., Maslow, C., Wu, Y., Vlahov, D., et al. (2005). Childhood sexual abuse and age at initiation of injection drug use. Am. J. Public Health. 95, 703-709.
    • Oranje, B., van Berckel, B.N., Kemner, C., van Ree, J.M., Kahn, R.S., and Verbaten, M.N. (2000). The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22, 293-302.
    • Ott, J. (2001). Pharmanopo-psychonautics: Human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J. Psychoactive Drugs 33, 273-282.
    • Price, R.K., Risk, N.K., Haden, A.H., Lewis, C.E., and Spitznagel, E.L. (2004). Post-traumatic stress disorder, drug dependence, and suicidality among male Vietnam veterans with a history of heavy drug use. Drug Alcohol Depend. 76(Suppl), S31-43.
    • Reed, P.L., Storr, C.L., and Anthony, J.C. (2006). Drug dependence enviromics: Job strain in the work environment and risk of becoming drug-dependent. Am. J. Epidemiol. 163, 404-411.
    • Reynaud-Maurupt, C., Chaker, S., Claverie, O., Monzel, M., Moreau, C., and Evrard, I. (2007a). Pratiques et opinions lieées aux usages des substances psychoactives dans l'espace festif “musiques eélectroniques” (St. Denis, France: OFDT).
    • Reynaud-Maurupt, C., Bello P.Y., Akoka, S., and Toufik, A. (2007b). Characteristics and behaviors of ketamine users in France in 2003. J. Psychoactive Drugs 39, 1-11.
    • Richman, J.A., Flaherty. J.A., and Rospenda, K.M. (1996). Perceived workplace harassment experiences and problem drinking among physicians: Broadening the stress/alienation paradigm. Addiction 91, 391-403.
    • Sarton, E., Teppema, L.J., Olievier, C., Nieuwenhuijs, D., Matthes, H.W., Kieffer, B.L., and Dahan, A. (2001). The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth. Analg. 93, 1495-1500.
    • Shimoyama, M., Shimoyama, N., Gorman, A.L., Elliott, K.J., and Inturrisi, C.E. (1999). Oral ketamine is antinociceptive in the rat formalin test: Role of the metabolite, norketamine. Pain 81, 85-93.
    • Siegel, R.K. (1978). Phencyclidine and ketamine intoxication: A study of four populations of recreational users. NIDA Res. Monogr. 21, 119-147.
    • Smith, G.S., Schloesser, R., Brodie, J.D., Dewey, S.L., Logan, J., Vitkun, S.A., Simkowitz, P., Hurley, A., Cooper, T., Volkow, N.D., et al. (1998). Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18, 18-25.
    • Spagnolo, P.A., Celentano, M., Dubla, A., and Badiani, A. (2011). Setting preferences for heroin versus cocaine taking in human co-abusers: Role of environmental variables in drug use and relapse. Behav. Pharmacol. 22(e-suppl. A), e21.
    • Sprenger, T., Valet, M., Woltmann, R., Zimmer, C., Freynhagen, R., Kochs, E.F., Tölle, T.R., and Wagner, K.J. (2006). Imaging pain modulation by subanesthetic S-(+)-ketamine. Anesth. Analg. 103, 729-737.
    • Stewart, C.E. (2001). Ketamine as a street drug. Emerg. Med. Serv. 30, 30-34.
    • Sunder, R.A., Toshniwal, G., and Dureja, G.P. (2008). Ketamine as an adjuvant in sympathetic blocks for management of central sensitization following peripheral nerve injury. J. Brachial Plex. Peripher. Nerve Inj. 3, 22-28.
    • Tellier, P.P. (2002). Club drugs: Is it all Ecstasy? Pediatric Ann. 31, 550-556.
    • Testa, A., Nencini, P., and Badiani, A. (2011). The role of setting in the oral self-administration of alcohol in the rat. Psychopharmacol. (Berl) 215, 749-760.
    • Topp, L., Breen, C., Kaye, S., and Darke, S. (2004). Adapting the Illicit Drug Reporting System (IDRS) to examine the feasibility of monitoring trends in the markets for “party drugs”. Drug Alcohol Depend. 73, 189-197.
    • Triffleman, E.G., Marmar, C.R., Delucchi, K.L., and Ronfeldt, H. (1995). Childhood trauma and post traumatic stress disorder in substance abuse inpatients. J. Nerv. Ment. Dis. 183, 172-6.
    • Vollenweider, F.X. and Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Rev. Neurosci. 11, 642-651.
    • Vollenweider, F.X., Vontobel, P., Øye, I., Hell, D., and Leenders, K.L. (2000). Effects of (S)-ketamine on striatal dopamine: a [11C] raclopride PET study of a model psychosis in humans. J. Psychiatr. Res. 34, 35-43.
    • Weir, E. (2000). Raves: A review of the culture, the drugs and the prevention of harm. Canadian Med. J. Assoc. 162, 1843-1848.
    • White, M.J. and Ryan, C. (1996). Pharmacological properties of ketamine. Drug Alcohol Rev. 15, 145-155.
    • WHO Expert Committee on Drug Dependence (2012). Ketamine Critical Review (Geneva: World Health Organization. Available at http://www.who.int/medicines/areas/quality_ safety/35thecddmeet/en/index.html.
    • Wolff, K. and Winstock, A.R. (2006). Ketamine. From medicine to misuse. CNS Drugs 20, 199-218.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article